SCHEMBL23701557

SCHEMBL23701557

CCOC(=O)NCCc1nnc(-c2ccccc2Nc2ccc(C(F)(F)F)cc2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.42
DHODH Q02127 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
ALDH1A1 P00352 3/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 1/20 0.38
FLT1 P17948 1/20 0.37
KDR P35968 1/20 0.37
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
THRB P10828 1/20 0.36
MAPT P10636 3/20 0.36
POLB P06746 3/20 0.35
HSD17B10 Q99714 2/20 0.35
GAA P10253 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701617 0.92 ABCG2 (0.46) DDX3XABCG2KMT2AMEN1ALDH1A1
SCHEMBL23701605 0.91 ABCG2 (0.44) DDX3XABCG2DHODHKMT2AMEN1
SCHEMBL22571358 0.89 HTT (0.46) ABCG2KMT2AMEN1ALDH1A1TSHR
SCHEMBL22556452 0.89 DDX3X (0.43) DDX3XABCG2KMT2AMEN1ALDH1A1
SCHEMBL23701624 0.88 ABCG2 (0.42) DDX3XABCG2KMT2AMEN1ALDH1A1
SCHEMBL29888335 0.87 KDR (0.43) DDX3XDHODHALDH1A1NPSR1FLT1
SCHEMBL23701608 0.86 DDX3X (0.46) DDX3XABCG2ALDH1A1NPSR1TP53
SCHEMBL22556403 0.85 SMN1; SMN2 (0.54) DDX3XABCG2DHODHKMT2AMEN1
SCHEMBL30463813 0.85 SMN1; SMN2 (0.54) DDX3XABCG2DHODHKMT2AMEN1
SCHEMBL22556459 0.83 DDX3X (0.41) DDX3XABCG2ALDH1A1TP53FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 DDX3X 611/4885ABCG2 2985/4885DHODH 2248/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 DDX3X 611/4885ABCG2 2985/4885DHODH 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.